Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMGEL vs AKNE-MYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
Treatment of acne vulgaris (FDA-approved),Topical treatment of inflammatory acne (FDA-approved),Ophthalmic infections: prophylaxis of neonatal conjunctivitis (off-label),Treatment of bacterial infections of the skin (off-label)
Topical treatment of acne vulgaris
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
Topical application of 2% solution twice daily to affected areas.
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 m L/min).
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces.
Not systemically absorbed to a clinically significant degree after topical application. If absorbed, erythromycin is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4.
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
70–80%, primarily to albumin.
Bound primarily to albumin (10-20%)
0.9–1.1 L/kg; indicates extensive extravascular distribution.
0.2-0.3 L/kg, indicating limited extravascular distribution (primarily extracellular fluid)
Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%.
Topical: 2-5% (minimal systemic absorption); oral: 75-85%
No dosage adjustment required for topical use.
No dosage adjustment required for topical use; systemic absorption negligible.
No dosage adjustment required for topical use.
No dosage adjustment required for topical use; systemic absorption negligible.
Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily.
Safety and efficacy not established in children under 12 years; for age ≥12 years, same as adult dosing.
No specific dose adjustment; use caution due to potential skin atrophy in elderly.
No specific adjustments; use with caution due to potential increased skin sensitivity.
No FDA black box warning for topical erythromycin.
None
May cause irritation, burning, stinging, or dryness at application site,Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic,Superinfection may occur with prolonged use,Potential for bacterial resistance with prolonged use
For external use only; avoid contact with eyes, mouth, and mucous membranes. May cause skin irritation, burning, stinging, or dryness. Reported cases of pseudomembranous colitis with topical use (rare). Use with caution in patients with hepatic impairment if significant systemic absorption occurs. Cross-resistance with other macrolides may develop. Use during pregnancy only if clearly needed (category B).
Hypersensitivity to erythromycin or any component of the formulation,Not for use in patients with known hepatic impairment (relative contraindication for systemic use, but topical use is generally safe)
Hypersensitivity to erythromycin or any component of the formulation. Concurrent use with pimozide or ergot alkaloids (potential for QT prolongation and ergotism, though systemic absorption low).
No known food interactions. Avoid alcohol as it may increase risk of gastrointestinal irritation if oral salicylates are also used.
No specific food interactions. Take with or without food. Avoid excessive intake of spicy or greasy foods, which may exacerbate acne.
EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester.
Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with topical use, but risk cannot be completely excluded. First trimester: low risk, but use only if clearly needed. Second and third trimesters: generally considered safe with minimal systemic exposure.
Tetracyclines are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants exists, but absorption of tetracyclines from milk is limited due to chelation with calcium. Caution is advised; alternative therapies preferred.
Erythromycin is excreted in human milk in small amounts. Topical Akne-Mycin results in negligible systemic absorption, making significant infant exposure unlikely. M/P ratio not reported for topical use; oral erythromycin M/P ratio is approximately 0.5. Caution is advised, but use is generally compatible with breastfeeding.
No dose adjustment required for EMGEL in pregnancy; however, tetracyclines are contraindicated after first trimester. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, decreased plasma protein binding) but no specific dose adjustment recommended due to contraindication. Use only when no alternative and clearly needed.
No dose adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) are not clinically relevant for topical Akne-Mycin due to minimal systemic absorption. Apply as directed regardless of pregnancy trimester.
Apply sparingly to affected area; avoid contact with eyes, mucous membranes, and open wounds. Monitor for systemic absorption if used on large body surface areas. Use caution in patients with renal impairment due to potential for salicylate toxicity. Do not use with other topical preparations containing methyl salicylate.
Akne-Mycin (erythromycin topical) is effective for mild to moderate acne vulgaris. It can be combined with benzoyl peroxide to reduce antibiotic resistance. Avoid use with other topical erythromycin products to prevent overuse. Monitor for local skin reactions like erythema, scaling, or itching.
Wash hands before and after application.,Apply only to intact skin, not on wounds or damaged skin.,Do not use with heating pads or bandages unless directed by doctor.,Avoid sun exposure to treated area as it may cause photosensitivity.,Discontinue if rash or irritation occurs and consult doctor.
Apply a thin layer to affected areas once or twice daily as directed.,Wash skin gently with mild soap and pat dry before application.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use more often than prescribed; overuse can increase irritation.,Inform your doctor if you develop severe redness, peeling, or discomfort.,Use sunscreen daily as this medication may increase sun sensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMGEL vs AKNE-MYCIN, answered by our medical review team.
EMGEL is a Topical Antibiotic that works by Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.. AKNE-MYCIN is a Topical Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-t RNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMGEL and AKNE-MYCIN depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMGEL is: Topical application of a thin layer to affected area twice daily; oral administration not applicable.. The standard adult dose of AKNE-MYCIN is: Topical application of 2% solution twice daily to affected areas.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMGEL and AKNE-MYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMGEL is classified as Category C. EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and te. AKNE-MYCIN is classified as Category C. Akne-Mycin (erythromycin topical) is Pregnancy Category B. No evidence of teratogenicity in animal studies; adequate human studies are lacking. Systemic absorption is minimal with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.